Clinical trial
Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus…
NCT00464165 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00464165 |
|---|---|
| Title | Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation |
| Official title | Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/Day or 20mg/Day, Versus Placebo, as an Aid to Smoking Cessation; Multiple Country, Randomized, Double-blind, 3-arm, 10-week Treatment, 40-week Follow-up |
| Acronym | STRATUS-EU |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Drug |
| Interventions | rimonabant |
| Enrollment | 789 |
| Start date | Nov 1, 2002 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Apr 23, 2007 |
| Last update posted | Dec 10, 2010 |
| Countries | Belgium, Denmark, France, Spain, Sweden, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: